Indaptus Therapeutics (NASDAQ:INDP – Get Rating)‘s stock had its “overweight” rating reiterated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price objective on the stock.
Indaptus Therapeutics Price Performance
Shares of NASDAQ INDP opened at $1.61 on Wednesday. Indaptus Therapeutics has a 1 year low of $1.25 and a 1 year high of $4.25. The firm has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.91.
Hedge Funds Weigh In On Indaptus Therapeutics
A number of institutional investors have recently modified their holdings of INDP. Northern Trust Corp purchased a new position in shares of Indaptus Therapeutics during the first quarter worth approximately $41,000. Renaissance Technologies LLC acquired a new stake in shares of Indaptus Therapeutics during the second quarter worth $51,000. State Street Corp acquired a new stake in shares of Indaptus Therapeutics during the first quarter worth $78,000. Strategy Asset Managers LLC acquired a new position in Indaptus Therapeutics during the third quarter valued at $120,000. Finally, Vanguard Group Inc. lifted its position in Indaptus Therapeutics by 18.7% during the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock valued at $969,000 after purchasing an additional 38,216 shares during the period. 6.87% of the stock is owned by hedge funds and other institutional investors.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria.
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.